The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | Selecting a therapeutic approach for patients with relapsed/refractory myeloma
Wee Joo Chng, MB ChB, MRCP, MRCPath, PhD, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, discusses the complexities of choosing a treatment strategy for relapsed/refractory (R/R) multiple myeloma (MM), highlighting key decision points such as whether a patient is refractory to lenalidomide or anti-CD38 antibodies. Prof. Chng emphasizes that with a variety of approved regimens available, treatment can be tailored based on prior therapies, potential toxicities, and the patient’s overall condition. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
